169 related articles for article (PubMed ID: 1744165)
1. Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours.
Punnonen J; Heinonen PK; Kuoppala T; Jansen CT; Punnonen R
J Cancer Res Clin Oncol; 1991; 117(6):587-92. PubMed ID: 1744165
[TBL] [Abstract][Full Text] [Related]
2. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.
Daraï E; Detchev R; Hugol D; Quang NT
Hum Reprod; 2003 Aug; 18(8):1681-5. PubMed ID: 12871882
[TBL] [Abstract][Full Text] [Related]
3. Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies.
Sipak-Szmigiel O; Włodarski P; Ronin-Walknowska E; Niedzielski A; Karakiewicz B; Słuczanowska-Głąbowska S; Laszczyńska M; Malinowski W
J Ovarian Res; 2017 Apr; 10(1):25. PubMed ID: 28376925
[TBL] [Abstract][Full Text] [Related]
4. Cytokines in peritoneal fluid of ovarian neoplasms.
de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
[TBL] [Abstract][Full Text] [Related]
5. Differential processing of type I and type III procollagens in the tumour cysts and peritoneal ascitic fluid of patients with benign and malignant ovarian tumours.
Zhu GG; Melkko J; Risteli J; Kauppila A; Risteli L
Clin Chim Acta; 1994 Sep; 229(1-2):87-97. PubMed ID: 7988058
[TBL] [Abstract][Full Text] [Related]
6. Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors.
Punnonen R; Teisala K; Kuoppala T; Bennett B; Punnonen J
Cancer; 1998 Aug; 83(4):788-96. PubMed ID: 9708947
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in the effusions of ovarian epithelial neoplasms.
Kutteh WH; Kutteh CC
Am J Obstet Gynecol; 1992 Dec; 167(6):1864-9. PubMed ID: 1471711
[TBL] [Abstract][Full Text] [Related]
8. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer.
Gastl G; Plante M; Finstad CL; Wong GY; Federici MG; Bander NH; Rubin SC
Br J Haematol; 1993 Mar; 83(3):433-41. PubMed ID: 8485049
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells.
Sowter HM; Corps AN; Smith SK
Int J Cancer; 1999 Nov; 83(4):476-80. PubMed ID: 10508482
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
11. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
[TBL] [Abstract][Full Text] [Related]
12. Measurement of human chorionic gonadotropin-related immunoreactivity in serum, ascites and tumour cysts of patients with gynaecologic malignancies.
Grossmann M; Hoermann R; Gocze PM; Ott M; Berger P; Mann K
Eur J Clin Invest; 1995 Nov; 25(11):867-73. PubMed ID: 8582453
[TBL] [Abstract][Full Text] [Related]
13. [Serum cytokines in patients with ovarian cancer and benign ovarian cysts].
Nowak M; Szpakowski M; Malinowski A; Wieczorek A; Maciołek-Blewniewska G; Wilczyński JR; Szpakowski A; Wierzbicka E; Małafiej E; Oszukowski P
Ginekol Pol; 2001 Dec; 72(12A):1444-8. PubMed ID: 11883294
[TBL] [Abstract][Full Text] [Related]
14. Host-tumor interaction in ovarian cancer. Spontaneous release of tumor necrosis factor and interleukin-1 inhibitors by purified cell populations from human ovarian carcinoma in vitro.
Burger RA; Grosen EA; Ioli GR; Van Eden ME; Brightbill HD; Gatanaga M; DiSaia PJ; Granger GA; Gatanaga T
Gynecol Oncol; 1994 Nov; 55(2):294-303. PubMed ID: 7959299
[TBL] [Abstract][Full Text] [Related]
15. Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms.
Micheli DC; Jammal MP; Martins-Filho A; Côrtes JRXM; Souza CN; Nomelini RS; Murta EFC; Tavares-Murta BM
Biomarkers; 2020 Sep; 25(6):474-482. PubMed ID: 32544350
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.
Wu S; Boyer CM; Whitaker RS; Berchuck A; Wiener JR; Weinberg JB; Bast RC
Cancer Res; 1993 Apr; 53(8):1939-44. PubMed ID: 8385577
[TBL] [Abstract][Full Text] [Related]
17. Measurement of glycodelin A in fluids of benign ovarian cysts, borderline tumours and malignant ovarian cancer.
Bischof A; Briese V; Richter DU; Bergemann C; Friese K; Jeschke U
Anticancer Res; 2005; 25(3A):1639-44. PubMed ID: 16033074
[TBL] [Abstract][Full Text] [Related]
18. Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6, (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas.
Asschert JG; Vellenga E; Hollema H; van der Zee AG; de Vries EG
Eur J Cancer; 1997 Nov; 33(13):2246-51. PubMed ID: 9470814
[TBL] [Abstract][Full Text] [Related]
19. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer.
Santin AD; Bellone S; Ravaggi A; Roman J; Smith CV; Pecorelli S; Cannon MJ; Parham GP
BJOG; 2001 Aug; 108(8):804-8. PubMed ID: 11510703
[TBL] [Abstract][Full Text] [Related]
20. Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts.
Sundfeldt K; Ivarsson K; Rask K; Haeger M; Hedin L; Brännström M
Anticancer Res; 2001; 21(1A):65-70. PubMed ID: 11299791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
